• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Marsha A. Moses, PhD


  • Pelton K, Coticchia CM, Curatolo AS, Schaffner CP, Zurakowski D, Solomon KR, Moses MA.Hypercholesterolemia Induces Angiogenesis and Accelerates Growth of Breast Tumors in Vivo.Am J Pathol. 2014 Jul;184(7):2099-110.
  • Foradori MJ, Chen Q, Fernandez CA, Harper J, Li X, Tsang PC, Langer R, Moses MA.Matrilin-1 is an inhibitor of neovascularization.J Biol Chem. 2014 Apr 1.
  • Guo P, You JO, Yang J, Jia D, Moses MA, Auguste DT.Inhibiting Metastatic Breast Cancer Cell Migration via the Synergy of Targeted, pH-triggered siRNA Delivery and Chemokine Axis Blockade.Mol Pharm. 2014 Feb 12.
  • Sreenivasan AK, Bachur CD, Lanier KE, Curatolo AS, Connors SM, Moses MA, Comi AM.Urine vascular biomarkers in Sturge-Weber syndrome.Vasc Med. 2013 Jun;18(3):122-8.
  • Jia D, Hasso SM, Chan J, Filingeri D, D'Amore PA, Rice L, Pampo C, Siemann DW, Zurakowski D, Rodig SJ, Moses MA.Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo.Blood. 2013 Jan 24;121(4):707-15.
  • Mannelqvist M, Stefansson IM, Wik E, Kusonmano K, Raeder MB, Øyan AM, Kalland KH, Moses MA, Salvesen HB, Akslen LA.Lipocalin 2 expression is associated with aggressive features of endometrial cancer.BMC Cancer. 2012;12:169.
  • Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotinen M, Hager MH, Insabato L, Moses MA, Demichelis F, Lisanti MP, Wu H, Klagsbrun M, Bhowmick NA, Rubin MA, D'Souza-Schorey C, Freeman MR.Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease.Am J Pathol. 2012 Nov;181(5):1573-84.
  • Yang J, McNeish B, Butterfield C, Moses MA.Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.FASEB J. 2012 Sep 14.
  • Govindarajan B, Willoughby L, Band H, Curatolo AS, Veledar E, Chen S, Bonner MY, Abel MG, Moses MA, Arbiser JL.Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia.Vascular Cell. 2012;4(1):11.
  • Guo P, You JO, Yang J, Moses MA, Auguste DT.Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity.Biomaterials. 2012 Nov;33(32):8104-10.
  • Roy R, Moses MA.ADAM12 induces estrogen-independence in breast cancer cells.Breast Cancer Res Treat. 2011 Mar 9.
  • Fernandez CA, Roy R, Lee S, Yang J, Panigrahy D, Van Vliet KJ, Moses MA.The anti-angiogenic peptide, Loop 6, binds IGF-IR.J Biol Chem. 2010 Dec 31;285(53):41886-95.
  • Dudley AC, Udagawa T, Melero-Martin JM, Shih SC, Curatolo A, Moses MA, Klagsbrun M.Bone marrow is a reservoir for pro-angiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors.Blood. 2010 Oct 28;116(17):3367-71.
  • Becker CM, Louis G, Exarhopoulos A, Mechsner S, Ebert AD, Zurakowski D, Moses MA.Matrix metalloproteinases are elevated in the urine of patients with endometriosis.Fertil Steril. 2010 Nov;94(6):2343-6.
  • Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK.Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.J Clin Oncol. 2010 Jun 10;28(17):2817-23.
  • Lee PS,Tsang SW,Moses MA,Trayes-Gibson Z,Hsiao LL,Jensen R,Squillace R,Kwiatkowski DJ.Rapamycin-insensitive Up-regulation of MMP2 and Other Genes in TSC2-deficient LAM-like Cells.Am J Respir Cell Mol Biol. 2010 Feb;42(2):227-34.
  • Roy R, Yang J, Moses MA.Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.J Clin Oncol. 2009 Nov 1;27(31):5287-97. Review.
  • Yang J, Moses MA.Lipocalin 2: a multifaceted modulator of human cancer.Cell Cycle. 2009 Aug;8(15):2347-52.
  • Chang SH,Kanasaki K,Gocheva V,Blum G,Harper J,Moses MA,Shih SC,Nagy JA,Joyce J,Bogyo M,Kalluri R,Dvorak HF.VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation.Cancer Res. 2009 May 15;69(10):4537-44.
  • Manfredi MA,Fox VL,Zurakowski D,Kutok JL,Glickman JN,Moses MA.Matrix metalloproteinases in the urine and tissue of patients with juvenile polyps: potential biomarkers for the presence of polyps.J Pediatr Gastroenterol Nutr. 2009 Apr;48(4):405-11.
  • Yang J,Bielenberg DR,Rodig SJ,Doiron R,Clifton MC,Kung AL,Strong RK,Zurakowski D,Moses MA.Lipocalin 2 promotes breast cancer progression.Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3913-8.
  • Roy R,Louis G,Loughlin KR,Wiederschain D,Kilroy SM,Lamb CC,Zurakowski D,Moses MA.Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.Clin Cancer Res. 2008 Oct 15;14(20):6610-7.
  • Manfredi MA, Zurakowski D, Rufo PA, Walker TR, Fox VL, Moses MA.Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease.Inflamm Bowel Dis. 2008 Aug;14(8):1091-6.
  • Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA.Urinary biomarkers predict brain tumor presence and response to therapy.Clin Cancer Res. 2008 Apr 15;14(8):2378-86.
  • Klagsbrun M, Moses MA.Obituary: M. Judah Folkman (1933-2008).Nature. 2008 Feb 14;451(7180):781.
  • Alwayn IP, Verbesey JE, Kim S, Roy R, Arsenault DA, Greene AK, Novak K, Laforme A, Lee S, Moses MA, Puder M.A critical role for matrix metalloproteinases in liver regeneration.J Surg Res. 2008 Apr;145(2):192-8.
  • Harper J, Yan L, Loureiro RM, Wu I, Fang J, D'Amore PA, Moses MA.Repression of vascular endothelial growth factor expression by the zinc finger transcription factor ZNF24.Cancer Res. 2007 Sep 15;67(18):8736-41.
  • Rickert D, Franke RP, Lendlein A, Kelch S, Moses MA.Influence of the surface structure of a multiblock copolymer on the cellular behavior of primary cell cultures of the upper aerodigestive tract in vitro.J Biomed Mater Res A. 2007 Nov;83(2):558-69.
  • Ge G, Fernandez CA, Moses MA, Greenspan DS.Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor.Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10010-5.
  • Smith ER, Manfredi M, Scott RM, Black PM, Moses MA.A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report.Neurosurgery. 2007 Jun;60(6):E1148-9; discussion E1149.
  • Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA.ADAM 12 cleaves ECM proteins: Correlation with cancer status and stage.J Biol Chem. 2004 Dec 3;279(49):51323-30.
  • Fernndez CA, Butterfield C, Jackson G, Moses MA.Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor.J Biol Chem. 2003 Oct 17;278(42):40989-95.
  • Yan L, Borregaard N, Kjeldsen L, Moses MA.The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL.J Biol Chem. 2001 Oct 5;276(40):37258-65.
  • Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA.Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model.Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3884-9.